Legend Biotech

Legend Biotech announced a leadership change on September 15, 2026. Legend Biotech appointed former Novartis International Chief Commercial Officer Ingrid Zhang as CEO, succeeding Interim CEO Alan Bash, to guide the cell therapy company’s next phase of growth.

What changed

Ingrid Zhang was named Chief Executive Officer. Alan Bash, who had served as Interim Chief Executive Officer since July 2026, will resume his role as President, CARVYKTI.

• Leader: Ingrid Zhang
• Role: Chief Executive Officer
• Effective: September 15, 2026
• Announcement date: September 15, 2026

Leadership background

Zhang most recently served as Chief Commercial Officer for Novartis International, where she also led the company’s China business and innovative medicines organization. Earlier in her career, she held leadership positions at AstraZeneca, Pfizer, and McKinsey and Company.

The mandate

Legend Biotech said its Board selected Zhang after a comprehensive search to guide the company through its next phase of growth and advance its mission of transforming patient care through cell therapy. Zhang said she would work with the team to advance the pipeline, expand impact, and execute on the long-term growth strategy.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: Legend Biotech leadership announcement.